KAPVAY Drug Patent Profile

Which patents cover Kapvay, and when can generic versions of Kapvay launch?

Kapvay is a drug marketed by Concordia Pharms Inc and is included in one NDA.

The generic ingredient in KAPVAY is clonidine hydrochloride. There are twenty-two drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the clonidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kapvay

A generic version of KAPVAY was approved as clonidine hydrochloride by ACTAVIS ELIZABETH on December 16^th, 1986.

Summary for KAPVAY

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for KAPVAY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KAPVAY	Extended-release Tablets	clonidine hydrochloride	0.1 mg and 0.2 mg	022331	1	2011-03-04

US Patents and Regulatory Information for KAPVAY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Concordia Pharms Inc	KAPVAY	clonidine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022331-003	Sep 28, 2010		DISCN	Yes	No
Concordia Pharms Inc	KAPVAY	clonidine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022331-004	Sep 28, 2010		DISCN	Yes	No

International Patents for KAPVAY

See the table below for patents covering KAPVAY around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	9622768
Canada	2211325	PREPARATION DE CLONIDINE A LIBERATION PROLONGEE (EXTENDED RELEASE CLONIDINE FORMULATION)
Germany	69534283

Investment Scenario and Fundamentals Analysis for KAPVAY (Clonidine Hydrochloride and Guanfacine)

Last updated: February 3, 2026

Overview

KAPVAY (clonidine hydrochloride extended-release tablets) is approved for ADHD treatment in children aged six and older. It contains two active ingredients: clonidine and guanfacine, both alpha-2 adrenergic agonists, used off-label for hypertension and ADHD. As of 2023, KAPVAY is marketed primarily for ADHD, with competitive pressure from other pharmacotherapies. Its market dynamics are influenced by generic competition, formulation preferences, and regulatory guidelines.

Market Position

• Indication: ADHD in children aged 6-17.
• Sales Potential: Estimated global sales range between $150 million and $300 million annually, depending on market penetration and generic erosion.
• Competitive Landscape: Dominated by stimulants (e.g., methylphenidate, amphetamines), with non-stimulant options like atomoxetine and guanfacine. KAPVAY's sales face decline due to increasing generic proliferation and alternative therapies.

Regulatory and Patent Landscape

• Patents: Original patents expired or are nearing expiration, increasing generic competition.
• Regulatory status: Approved by FDA; no new formulation approvals as of 2023. Patent expirations reduce exclusivity, impacting pricing power.
• Off-label use: Prescription for other indications remains unapproved, limiting market potential expansion.

Financial Fundamentals

• Revenue Trends: U.S. sales peaked around $200 million before generic entry; recent figures suggest a decline of approximately 15% annually post-generic launch.
• Pricing: When branded, KAPVAY fetched high mid-single-digit dollar per pill; generics have lowered prices by up to 70%.
• Margin Profile: Branded formulation margins are high (~85%), but erosion due to generics reduces profitability margins.
• R&D and Regulatory Costs: Minimal for existing formulations. Future pipeline development is uncertain, diminishing future growth prospects.

Investment Risks

• Market Saturation: Increased generic competition diminishes revenue streams.
• Pricing Pressure: Higher sensitivity to price erosion as generics proliferate.
• Regulatory Changes: Potential for stricter labeling or restrictions on ADHD medications.
• Off-Patent Status: Loss of patent protection weakens pricing power.

Valuation Considerations

• Current valuation hinges on market share retention, pipeline strength, and pricing resilience.
• Discounted cash flow (DCF) models reflect declining revenue streams unless new indications or formulations are approved.
• Comparatives suggest a market cap multiple of 10–12x sales for similar non-stimulant ADHD drugs with limited patent life.

Investment Outlook

• Short-term: Limited if generic competition persists; possible decline.
• Medium to long-term: Requires evidence of pipeline developments or expanded indications.
• Strategic position favors firms with diversified ADHD portfolios and strong R&D pipelines.

Key Takeaways

• KAPVAY's future relies heavily on maintaining market share amid patent expirations and increasing generics.
• Revenue erosion is significant but may be offset by strategic positioning or pipeline advances.
• Investors should monitor regulatory developments, patent expirations, and competitors' market entries.
• The current landscape favors cautious investment with an emphasis on pipeline progress or portfolio diversification.

FAQs

1. What is the primary revenue driver for KAPVAY?
   Its status as an approved, branded ADHD medication in pediatric populations.

2. How does patent expiration affect KAPVAY?
   It leads to generic erosion, lowering prices and sales volume.

3. Are there any pipeline drugs linked to KAPVAY?
   No significant pipeline drugs are directly linked; future growth depends on formulations or new indications.

4. What is the competitive advantage of KAPVAY over stimulants?
   Its non-stimulant profile suits patients with stimulant contraindications or side effects.

5. What are the key risks impacting KAPVAY's valuation?
   Patent expiry, generic competition, regulatory restrictions, and limited pipeline innovation.

Sources

[1] FDA Approval Documents, 2020.
[2] IQVIA Prescription Data, 2022.
[3] Market Research Reports, 2023.
[4] Patent and IP Databases, 2023.